China3D printingNet news on June 24,3D printingMachine manufacturer 3D Systems announced that it has reached a joint development agreement with CollPlant, a regenerative medicine company, to develop breast reconstruction treatments. biology3D printingSoft tissue structure.
Combined with the implementation of breast implants, the soft tissue structure will be used to provide support for the lower breast and expand the implant pocket, increasing the overall coverage of the implant. Using their joint expertise in 3D bioprinting, the two companies will personalize these structures to better match the patient’s anatomy. The ultimate goal is to increase the success rate of breast reconstruction surgery for cancer survivors.
The news came after 3D Systems announced in January that it intends to increase its investment in 3D bioprinting and regenerative medicine.
Dr. Jeffrey Graves, President and CEO of 3D Systems, said: “Through this project that we carried out in collaboration with CollPlant, we are exploring a new application that can provide new reconstruction treatments for breast cancer survivors. Projects that have such a positive impact are encouraging.”
A 3D bioprinted soft tissue scaffold with vascularization channels designed and produced by 3D Systems and CollPlant. Photo courtesy of 3D Systems.
The problem of breast cancer
The World Health Organization pointed out that 2.3 million women worldwide were diagnosed with breast cancer last year. It is the most common female cancer in the world, with nearly 700,000 deaths every year.
The vast majority of people diagnosed with this disease require partial or complete removal of breast tissue. However, with modern treatments, the survival rate exceeds 90%, which means that more and more women are seeking better breast reconstruction treatments.
Most of these breast reconstruction operations use soft tissue matrices from human cadavers or animals, but these sources are in short supply, and the variability of treatment methods is too large to be considered reliable. By using foreign mammalian tissues, there is also the risk of triggering an immune response, which slows the healing process.
CollPlant CEO Yehiel Tal added: “We have teamed up with 3D Systems to provide a renewable soft tissue matrix, which may significantly increase the potential market for soft tissue enhancement in breast implant surgery. Regenerative solutions can promote the growth of new tissues. Improve safety, eliminate product differences, and enhance results.”
CollPlant previously worked with 3D Systems to bioprint many tissue scaffolds (pictured). Photo from CollPlant.
Joint Development Agreement
According to the joint development agreement, the two companies will use the bio-ink based on recombinant human collagen (rhCollagen) to 3D bioprint the patient-specific soft tissue matrix, which is an expert at CollPlant. The company uses a proprietary plant-based technology to produce 3D printable rhCollagen bio-ink, which is reportedly the same as the natural collagen we produce every day.
The matrix combines mechanical properties with the properties of promoting cell infiltration and proliferation, and further promotes tissue regeneration at the implanted site. Both 3D Systems and CollPlant believe that this project will produce tissue matrices with far better performance than currently possible, with consistency and safety. Since the treatment will be based on plant sources, there will be no risk of immune response and no shortage of supply.
Tal concluded: “We are very pleased to deepen our cooperation with 3D Systems as part of CollPlant’s strategy as a leader in regenerative medicine.”
3D bioprinted soft tissue scaffold. Photo courtesy of 3D Systems.
The CollPlant co-development agreement is the latest in a 3D Systems partnership and acquisition, all of which are part of the regenerative medicine roadmap. Just last month, the company announced the acquisition of Allevi, a 3D bioprinter developer based in Pennsylvania. Allevi was founded in 2014, and its 3D bioprinting technology and bio-ink have been found in more than 380 medical and pharmaceutical laboratories around the world.
Elsewhere, 3D Systems had previously partnered with the Belgian biotechnology company Antleron to develop regenerative products for personalized patient care. Through cooperation, the two companies are committed to transforming from static 2D cell culture to usable, bioreactor-based 3D cell culture, thereby realizing new methods for the production of medical implants, vaccines, cell therapies, and more.
China3D printingNet compile article!
(Editor in charge: admin)
0 Comments for “3D Systems and CollPlant develop biological 3D printed soft tissue for breast reconstruction treatment”